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Summary
Head and neck squamous cell carcinoma is the sixth most common malignancy. High morbidity and mortality, lack 
of response to radio-and chemotherapy and signifi cant reduction in the quality of life in patients after surgical procedures 
in the head and neck region stress the need for more eff ective methods of diagnosis, treatment and prevention of disease 
recurrence. In the past, pathologist only defi ned the diagnosis, today pathologist also determines the prognostic and predic-
tive factors that are important in the treatment of patients. This places the pathologist in the core of in a multidisciplinary 
team for head and neck cancer and decision making.
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SPECIFIČNOSTI PATOHISTOLOŠKE ANALIZE KARCINOMA GLAVE I VRATA
Sažetak
Karcinom pločastih stanica glave i vrata je na šestom mjestu zloćudnih tumora. Karakterizira ga visoka incidencija i 
visoka smrtnost, također ne pokazuje očekivani odgovor na zračenje i kemoterapiju, a vidljiva je značajno umanjena kvali-
teta života u bolesnika nakon kirurškog liječenja. Sve to zahtjeva traženje mnogo učinkovitijih metoda u dijagnosticiu i lije-
čenju kao i prevenciji bolesti. U prošlosti je patolog samo postavio dijagnozu, danas treba odrediti prognostičke i prediktiv-
ne čimbenike koji su važni za liječenje bolesnika. Patolog je postao jedna od ključnih osoba u multidisciplinarnom timu 
karcinoma glave.
KLJUČNE RIJEČI: glava i vrat, karcinom pločastih stanica, patologija
Squamous cell cancer of the head and neck is 
common worldwide. The prognosis for early stage 
disease is good, but for patients with advanced 
disease it has chaged very litt le in the past 20 
years. Researches have identifi ed mutations in 
many genes, and the results of molecular research 
gives hope to the possibility of bett er treatment 
and prognosis of patients. Multidisciplinary teams 
are essential for optimal management
Head and neck squamous cell carcinoma 
(HNSCC) develops from the alterations of the sur-
face epithelium include the clinical and pathologic 
terms known under the common histopathologi-
cal term - dysplasia. Dysplasia and intraepithelial 
neoplasia represent a spectrum of abnormal epi-
thelial maturation (dysplasia) and cellular abera-
tions (atypia) that may or may not precede an in-
vasive carcinoma, but the changed epithelium has 
a high risk of progression to squamous cell cancer. 
Malignant transformation of the mucosal lining is 
a genetic process resulting from accumulation of 
multiple genetic alterations that dictates the fre-
quency and pace of progression to invasive carci-
noma.Loss of heterozygosity (LOH) studies indi-
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cate that the earliest alterations appear to target 
specifi c genes located on chromosome 3p,9p21 
(CDKN2A), and 17p13 (TP53). Alterations that 
tend to occur in association with higher grades of 
dysplasia and SCC include cyclin D1 amplifi ca-
tion, PTEN inactivation, and LOH at 13q21,
14q32,p,8,4q2, and 10q23 (1). There are no indi-
vidual markers that reliably predict malignant 
transformation of dysplastic lesions.
Precursor lesions are strongly associated 
with tobacco smoking and alcohol abuse, and es-
pecially a combination of these two. The risk of 
developing these lesions increases with duration 
of smoking, the type of tobacco and the practice of 
deep inhalation. Additional etiological factors are: 
industrial pollution, specifi c occupational expo-
sures, nutritional defi ciency, and hormonal dis-
turbance. The role of human papillovirus (HPV) 
infection in precursor lesions may represent an 
incidental HPV colonization rather than true in-
fection. Finally, identifying an accurate biomarker 
for the premalignant state would aid in diagnosis 
and also allow premalignancy rather than carci-
noma to be an endpoint in clinical trials (1). Dis-
covery of a biomarker to identify those lesions 
likely to progress to cancer would represent a con-
siderable advancement in patient care.
The histopathologic interpretation and grad-
ing of epithelial dysplastic changes in the upper 
aerodigestive tract is imprecise and subjective. 
Various classifi cation have evolved to describe the 
spectrum of histological changes in relation to 
their malignant potential and close collaboration 
between the pathologist and the clinician is essen-
tial in each individual case for interpretation of 
their respective fi ndings and their importance in 
therapy and prognosis.
Some precursor lesions are self-limiting and 
reversible, particularly if apparent etiologic fac-
tors are removed. Others persist and some prog-
ress to SCC. The likelihood of malignant change 
directly relates to the severity of dysplasia. How-
ever, it is clear that malignancy can develop from 
any grade of dysplasia or even from morphologi-
cally normal epithelium. Dysplastic lesions classi-
fi ed as moderate to severe have an 11% rate of 
 malignant transformation. Diagnosis of precursor 
lesions implies a need for close follow-up and 
complete excision. Dysplastic lesions are frequent-
ly found in the surgical margins of invasive SCC, 
meaning such lesions can remain in the patient.
These unresected fi elds act as an important source 
of local recurrence and second primary tumors 
that often occur in patients treated for HNSCC (2).
The clinical or gross appearance of SCC is 
quite variable and includes ulcerated, fl at, exo-
phytic, verrucoid or papillary growths. The histo-
logic appearance of invasive SCC may be as vari-
able as the gross appearance without specifi c cor-
relation between the gross appearance and the 
histopathologic fi ndings.
According to the classifi cation of the World 
Health Organization, SCC of head and neck is di-
vided in some diff erent types: conventional, verru-
cous, basaloid, papillary, spindle cell (sarcomatoid), 
acantholytic, adenosquamous, cuniculatum (1).
It is known that conventional type of SCC ex-
press epithelial markers such as cytokeratins. Ver-
rucous carcinoma is a non-metastasizing variant 
of well-diff erentiated SCC, but basaloid SCC is a 
high-grade variant of this tumour. It is an aggres-
sive, rapidly growing tumour characterized by an 
advanced stage at the time of diagnosis (very of-
ten cervical lymph node metastases) and a poor 
prognosis. Neuroendocrine markers and HMB-45 
are negative, but this tumour may express neuron 
specifi c enolase (NSE) what is considered nonspe-
cifi c. Variable expression can be seen with vimen-
tin, S-100 protein, and actin.
Papillary SCC is a distinct variant with favor-
able prognosis. Patient with his tumour tend to 
have a bett er prognosis compared to those with 
site-and stage-matched conventional SCC (2).
Spindle cell carcinoma is biphasic tumour com-
posed of a squamous cell carcinoma, either in situ 
and/or invasive, and a malignant spindle cell com-
ponent with a mesenchymal appearance, but of 
epithelial origin. Synonyms include sarcomatoid 
carcinoma, carcinosarcoma, metaplastic carcino-
ma, pseudosarcoma and Lane tumour. Spindle 
cell carcinoma is very aggressive tumour, most 
frequently occurs in men after the 60 year of age of 
life. There is mounting molecular evidence that 
this tumour is a monoclonal epithelial neoplasm 
with a divergent (mesenchymal) diff erentiation, 
rather than a collision tumour, and immunohisto-
chemistry may be of value (3).
Acantholytic and adenosquamous carcinoma are 
also aggressive tumors.
Carcinoma cuniculatum is a rare variant of oral 
cancer characterized with proliferation of strati-
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fi ed squamous epithelium in broad process with 
keratin cores and keratin-fi lled crypts which seem 
to burrow into bone tissue, but lack obvious cyto-
logical features of malignancy. Clinical-pathologi-
cal correlation is often needed to make the diagno-
sis (1).
Treatment of patients with SCC depends on 
pathohistological prognostic factors. The prog-
nosic parameters are as follows.
Tumour size
The overall 5-year survival has been reported 
to vary in range according to tumour size( T1/T2 
as low-risk umours and T3/T4 as high-risk ). The out-
come is greatly infl uenced by stage of the disease, 
and prognosis also depends or varies with tumour 
primary site, nodal involvement, tumour thick-
ness, and status of surgical margins. The tumour 
size usually aff ects choice and outcome of treat-
ment. It also aff ects the surgeon ability to achieve 
complete resection, especially in deep invading 
tumors. Increased tumour size has been linked to 
cervical involvement, high recurrence rate, and 
poor prognosis (4).
Tumour volume
Tumour volume or tumour thickness is close-
ly related to lymph node metastasis, and it is be-
lieved that it refl ects the aggressiveness of tumour 
growth. It is believed that the amount and nature 
of lymph node metastasis are closely related to 
size and thickness of tumour. It has been found 
that the size of lymph node involvement is closely 
related to tumour volume (thickness). Therefore, 
it is widely accepted that thickness is more accu-
rate predictor of sub-clinical nodal metastasis, lo-
cal recurrence, and survival than tumour size (5).
Invasive front
Tumour growth at the invasive front can 
show an expansive patt ern, an infi ltrative patt ern 
or both. Expansive growth patt ern is characterised 
by large tumour islands with well-defi ned push-
ing margins and is associated with a bett er prog-
nosis. Infi ltrative growth patt ern is characterised 
by scatt ered small irregular cords or single tumour 
cells, with poorly defi ned infi ltrating margins and 
is associated with a more aggressive course. Some 
guidelines recommend categorizing tumors into 
cohesive, and non-cohesive fronts (6).
Resection margins
The complete excision of tumour is the most 
important principle of oncologic surgery. Nega-
tive resection margins are generally associated 
with decreased recurrence and improved surviv-
al. Resection margins have not been precisely de-
fi ned but distances of at least 5 mm or greater are 
desired (7). The patologist is highly responsible 
for determining the state of resection margins. 
Therefore it is necessery to ink the margins before 
taking a tissue samples.
Degree of diff erentiation
Invasive SCC includes keratinizing and non-
keratinizing carcinoma, and according to the de-
gree of keratinisation, cellular and nuclear pleo-
morphism, and mitotic activity is categorised 
from well to poorly diff erentiated. The degree of 
diff erentiation is a signifi cant predictor of locore-
gional failure and tumour recurrence, but grading 
by diff erentiation is of limited prognostic value, as 
compared to patt ern of invasion (8).
Lymph node involvement
Bad prognosis is expected in patients with 
ispilateral, contralateral or bilateral nodal involve-
ment. The worst is bilateral then contralateral, 
then ipsilateral. The size of nodal involvement is a 
very important determent, and extracapsular in-
vasion was identifi ed as an important predictor of 
regional recurrence, distant metastasis, and thus, 
overall survival (4). A pathologist is a key person 
in determining the involvement of the number of 
lymph node metastases as determining the extra-
capsular spread in lymph nodes. Also, must deter-
mine the size of the largest metastasis in the lymph 
node.
Perineural and endoneural invasion
Perineural and endoneural invasion is strong-
ly associated with tumour size, histological grad-
ing, invasive front and nodal involvement. The 
perineural spread is aff ecting overall prognosis 
and survival, because the perineural and endo-
neural invasion means spreading of the tumour 
cells up to base of the skull as the tumour cells 
spread easily through the nerve and surrounding 




Lymphovascular invasion is associated with 
an increased propensity for lymph node and/or 
distant metastases. It tend to occur in aggressive 
SCC and is associated with recurrence and poor 
survival (10).
Molecular biologic studies have been exten-
sively used in patients with head and neck cancers 
in the evaluation of pathogenesis of disease and as 
potential determinants in prognosis. Deletion al-
lelic inbalance, or LOH on short arm (p) of chro-
mosome 3 occurs in SCC and have been shown to 
be associated with aggressive biologic behavior, 
as well as having prognostic and therapeutic im-
portance (11,12).
Some authors used molecular biologic mark-
ers to assess histopathologic negative surgical 
margin and negative lymph nodes for patients 
with SCC. They also found p53 mutations in tu-
mour resection margins and lymph nodes that 
were free of tumour by conventional histologic ex-
amination. The presence of p53 mutations in tu-
mour-freesurgical margins ad lymph nodes carried 
a substantially higher risk of local recurrent dis-
ease than in patients without p53 mutations (13). 
Today it is very well known that the expression of 
epidermal growth factor receptor (EGFR) may be 
a biomarker for an improved response to therapy 
and a predictive marker as well (14). Elevated lev-
els of EGFR expression have been associated to a 
poor clinical outcome (15). According to novel 
data, the PI3K-PTEN-AKT pathway is also fre-
quently activated in SCC of head and neck (16).
Patients with HPV-positive tumors are asso-
ciated with a more favorable clinical outcome re-
gardless of treatment modalities, and this may be 
related to immune surveillance to viral antigens 
(16). The bett er prognosis associated with HPV 
status has also been observed in high-grade basa-
loid SCC of the oropharynx (17). Recent studies 
indicate that a small population of cancer cells is 
highly tumorogenic, and that existence of cancer 
stem cells may be the reason for lack of eff ective-
ness of previous treatment methods. Targeted 
elimination of these cells is considered to provide 
a new framework for head and neck cancer treat-
ment (18). The emergence of molecular biology 
with its new prognostic and ultimately, therapeu-
tic tools represents an enormous opportunity. Un-
fortunatelly, the biologic markers are very expen-
sive, and laboratory standardization of biologic 
marker techniques and variability in interpreta-
tion of tissue results comprimise the diagnostic 
signifi cance of these markers.
CONCLUSION
Early detection of precancer lesions coupled 
with early interventation could signifi cantly im-
prove patient outcome and reduce mortality. Con-
ventional histopathology is currently unable to 
predict accurately which individual lesions from 
oral potentially malignant disorders spectrum 
will transform to squamous cell carcinoma. There-
fore the close collaboration of pathologist and the 
clinician in everyday treatment decision making is 
essential.
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